Who are Gemcitabine and cisplatin / carboplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemcitabine-Cisplatin chemotherapy, Gemcitabine & oxaliplatin, Gemcitabine + carboplatin, Gemcitabine and Oxaliplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-and-cisplatin-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gemcitabine and cisplatin / carboplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine and cisplatin / carboplatin (Gemcitabine and cisplatin / carboplatin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (nucleoside analog + platinum agent). Area: Oncology.

phase 3 Chemotherapy combination (nucleoside analog + platinum agent) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine and cisplatin / carboplatin (Gemcitabine and cisplatin / carboplatin) — Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Gemcitabine and cisplatin/carboplatin is a chemotherapy combination that damages cancer cell DNA through complementary mechanisms to inhibit tumor growth.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gemcitabine and cisplatin / carboplatin TARGET	Gemcitabine and cisplatin / carboplatin	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)
Gemcitabine-Cisplatin chemotherapy	Gemcitabine-Cisplatin chemotherapy	Simcere Pharmaceutical Co., Ltd	marketed	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)
Gemcitabine & oxaliplatin	Gemcitabine & oxaliplatin	3D Medicines (Sichuan) Co., Ltd.	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (gemcitabine via ribonucleotide reductase inhibition and DNA incorporation; oxaliplatin via platinum-DNA adducts)
Gemcitabine + carboplatin	Gemcitabine + carboplatin	AstraZeneca	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)
Gemcitabine and Oxaliplatin	Gemcitabine and Oxaliplatin	New Mexico Cancer Research Alliance	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (nucleoside analog + platinum agent) class)

3D Medicines (Sichuan) Co., Ltd. · 1 drug in this class
AstraZeneca · 1 drug in this class
New Mexico Cancer Research Alliance · 1 drug in this class
Simcere Pharmaceutical Co., Ltd · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine and cisplatin / carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-and-cisplatin-carboplatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab